Skip to contentpdufa.bio

revumenib (informs SNDX-62122)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

revumenib (informs SNDX-62122) is a Syndax Pharmaceuticals Inc program in myelofibrosis. Its next catalyst is a Readout in Q4 2027. 1 FDA decision on record below.

SNDX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

revumenib (informs SNDX-62122) is marketed as Revuforj (revumenib); the events below include those tracked under the brand name. Indication under review: Myelofibrosis. Sponsor: Syndax Pharmaceuticals Inc (SNDX). We track 2 catalyst events for this program: 1 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Oct 24, 2025 ✓ ApprovedSNDXReadout · Q4 2027SNDX

Questions

When is revumenib (informs SNDX-62122)'s next FDA decision or readout?

The next tracked catalyst for revumenib (informs SNDX-62122) is a Readout in Q4 2027.

What happened at revumenib (informs SNDX-62122)'s most recent FDA decision?

On Oct 24, 2025 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

What is revumenib (informs SNDX-62122) used for?

In our records revumenib (informs SNDX-62122) is under review or in development for Myelofibrosis.

Who makes revumenib (informs SNDX-62122)?

Syndax Pharmaceuticals Inc (SNDX).

Has revumenib (informs SNDX-62122) been approved by the FDA?

Yes. The FDA approved an application for revumenib (informs SNDX-62122) on Oct 24, 2025; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.